| Nomenclature | leukocyte receptor tyrosine kinase | anaplastic lymphoma receptor tyrosine kinase |
| Common abreviation | LTK | ALK |
| HGNC, UniProt | LTK, P29376 | ALK, Q9UM73 |
| EC number | 2.7.10.1 | 2.7.10.1 |
| Inhibitors | – | GSK‐1838705A (pIC50 9.3) [161], compound 8e [PMID: 24432909] (pIC50 9.1) [76], crizotinib (pIC50 9) [35], NVP‐TAE684 (pK d 9) [38], compound 25b [PMID: 22564207] (pIC50 8.7) [59] |
| Selective inhibitors | – | ceritinib (pIC50 9.7) [120] |
| Comments | – | crizotinib appears to be a selective ALK inhibitor acting on the tyrosine kinase activity [58] |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.